Blood Cancer United Inc 2024 AR2
The report highlights the 75th anniversary of The Leukemia & Lymphoma Society (LLS) and its ongoing efforts to cure blood cancer and support patients. In 2024, LLS increased its multi-year research investment to $332.3 million, awarded $10.8 million in Equity in Access research grants, and helped more than 15,000 patients through its Urgent Needs program. The organization also advocated for policies protecting patients from medical debt in nine states and helped cap out-of-pocket drug costs for Medicare Part D beneficiaries. LLS established a bold goal to enable blood cancer patients to gain more than one million years of life by 2040.
Company: Blood Cancer United Inc
Sector: Healthcare & social services
Country: United States
Year: 2024
Type: AR2
Pages: 17
Back to company
Blood Cancer United Inc
Annual Report
The report highlights the 75th anniversary of The Leukemia & Lymphoma Society (LLS) and its ongoing efforts to cure blood cancer and support patients. In 2024, LLS increased its multi-year research investment to $332.3 million, awarded $10.8 million in Equity in Access research grants, and helped more than 15,000 patients through its Urgent Needs program. The organization also advocated for policies protecting patients from medical debt in nine states and helped cap out-of-pocket drug costs for Medicare Part D beneficiaries. LLS established a bold goal to enable blood cancer patients to gain more than one million years of life by 2040.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available